Live Virus Vaccines Against Human Respiratory Syncytial Virus
人呼吸道合胞病毒活疫苗研究进展

Human respiratory syncytial virus (RSV) is the major cause of bronchiolitis and pneumonia in infants and young children worldwide, and it is also a significant cause of morbidity and mortality in immunocompromised patients and the elderly. For these reasons, there is a need to develop vaccine effective against RSV. Currently, sereral vaccine development strategies are being explored including subunit vaccines and live virus vaccines, etc. The live virus vaccines, either live attenuated RSV vaccines or live attenuated virus vectors encoding RSV protective antigens (vectored vaccines), are the potential candidate vaccines for seronegative infants, and have been paid more attention. Among them, the rA2cp248/404/1030?SH virus has shown to be highly attentuated and moderately immunogenic in infants no more than two months of age, absent with enhanced RSV disease during subsequent natural RSV infection in the vaccinees. Therefore, the current status and development of RSV live vurs vaccines are reviewed.